SynAct Pharma has received useful external validation for lead asset resomelagon’s dengue programme, with a World Health Organization (WHO)-...
SynAct Pharma has reported further analysis of the Phase IIb ADVANCE study (testing resomelagon in rheumatoid arthritis), providing a cleare...
SynAct’s Q226 results marked a strategically important period in defining resomelagon’s clinical and commercial opportunity.
After the readout of ADVANCE in June, which showed a strong tendency towards effect across the two major measurements (ACR20 and DAS28-CRP),...
SynAct Pharma reported Q226 operating expenses of SEK24.
Redeye views the term sheet and potential for a commercial license agreement with Hipolabor as a logical extension of the clinical trial und...
SynAct Pharma has signed a term sheet with established Brazilian pharmaceutical company Hipolabor for the co-development and commercialisati...
SynAct Pharma has reported that some early preclinical data have shown that resomelagon may reduce inflammation and joint damage associated ...
SynAct has reported top-line results from its Phase IIb ADVANCE study evaluating resomelagon in newly diagnosed, treatment-naïve patients wi...
We update our base case after having analysed the ADVANCE data.
Redeye views the topline data as confirming a bell-shaped dose-response with resomelagon.
Redeye comments on SynAct Pharma's Q1 report. The main event since our Q4 update was the directed share issue of SEK52m, which strengthens t...
SynAct Pharma’s FY25 results reflect a year of solid execution, highlighted by the continued advancement of lead asset resomelagon in the Ph...
Redeye comments on SynAct Pharma's directed share issue of gross cSEK52m.
Redeye reviews SynAct Pharma's Q4 report. A new European study in respiratory insufficiency was initiated in February.
Redeye comments on the full recruitment of the phase IIb ADVANCE study in RA with 240 patients.
Redeye is optimistic about the new investigator-sponsored phase II trial in respiratory infections, seeing it as improving the investment ca...
SynAct Pharma is focused on inflammation resolution therapeutics.
Redeye reviews SynAct Pharma's Q3 report. The ADVANCE study is progressing and on track to enrol all patients before year-end 2025.
Redeye views Hunter Capital's purchase of shares and warrants from Heights Capital Management as opening the way for further share price inc...
Redeye comments on SynAct Biopharma’s Q2 report. After a directed share issue, loan agreement with Hunter Capital and HCM exercising warrant...
Redeye is optimistic about the second warrant conversion from HCM.
Redeye comments on the conversion of warrants and Cantargia's deal yesterday.
Redeye updates its base case of Synact following the directed share issue and new programme in polymyalgia rheumatica, which broadens resome...
Redeye is positive about SynAct’s new directed issue and loan agreement with Hunter Capital, both of which have attractive conditions for th...
Redeye comments on SynAct's Q1 report, which includes the initiation of a new phase II study in Dengue fever and new patents.
Redeye is optimistic about the start of a well-sized phase II study in patients with Dengue fever and provides an updated base case.
Redeye comments on Synact's Q4 report. Synact raised in total SEK65m from a combined rights and directed share issue in December-January.
Redeye comments on SynAct’s successful rights issue.
Redeye initiates coverage of SynAct Pharma, a biotech company advancing a novel approach to controlling inflammation through resolution rath...
